ContextVision

Less than 1K followers

CONTX

Oslo Børs

Medical Equipment & Services

Health Care

Overview

Investor consensus

ContextVision is a medical technology company. The company specializes in image analysis and artificial intelligence. The company's products include advanced image enhancement software for ultrasound, MRI, X-ray and mammography. The software is used by hospitals and research institutes worldwide. The company was founded in 1983 and is headquartered in Stockholm.

Market cap

-

Turnover

-

Revenue

134.35M

EBIT %

22.81 %

P/E

-

Dividend yield-%

-

Financial calendar

19.2

2026

Annual report '25

8.5

2026

Interim report Q1'26

12.5

2026

General meeting '26

All

Press releases

ShowingAll content types

Regulatory press releaseyesterday

ContextVision AB: Transactions made under the buy-back programme

Press release12/10/2025, 12:08 PM

ContextVision initiates the clinical phase of its point-of-care ultrasound innovation venture to advance liver disease diagnostics

Regulatory press release12/2/2025, 5:45 PM

ContextVision AB: Transactions made under the buy-back programme

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Regulatory press release12/1/2025, 10:25 AM

CONTX: Financial calendar

Regulatory press release11/21/2025, 4:10 PM

ContextVision AB: Transactions made under the buy-back programme

Regulatory press release11/12/2025, 4:11 PM

ContextVision AB: Transactions made under the buy-back programme

Regulatory press release11/6/2025, 7:00 AM

ContextVision AB: Q3 interim report 2025 – Navigating market uncertainty while making solid progress with our Data Quality initiative

Regulatory press release11/3/2025, 3:50 PM

ContextVision AB: Transactions made under the buy-back programme

Regulatory press release10/23/2025, 3:08 PM

ContextVision AB: Transactions made under the buy-back programme

Regulatory press release10/14/2025, 3:50 PM

ContextVision AB: Transactions made under the buy-back programme

Regulatory press release10/3/2025, 5:45 PM

ContextVision AB: Transactions made under the buy-back programme

Regulatory press release9/24/2025, 4:00 PM

ContextVision AB: Transactions made under the buy-back programme

Regulatory press release9/15/2025, 4:00 PM

ContextVision AB: Transactions made under the buy-back programme

Regulatory press release9/3/2025, 7:00 AM

ContextVision - Initiation of share buyback program

Regulatory press release8/26/2025, 6:00 AM

CONTX: ContextVision publishes Webcast for the Q2 report 2025

Regulatory press release8/26/2025, 6:00 AM

ContextVision AB: Q2 interim report 2025 - Customers pressured by trade uncertainty - We continue to invest to build tomorrow's solutions

Press release8/26/2025, 6:00 AM

ContextVision AB: ContextVision publishes Webcast for the Q2 report 2025

Regulatory press release5/30/2025, 6:00 AM

CONTX: ContextVision and AMRA Medical join forces to advance multimodal imaging in liver disease diagnostics

Press release5/30/2025, 6:00 AM

ContextVision AB: ContextVision and AMRA Medical join forces to advance multimodal imaging in liver disease diagnostics

Regulatory press release5/13/2025, 1:45 PM

ContextVision AB: BULLETIN FROM THE ANNUAL GENERAL MEETING OF CONTEXTVISION AB (PUBL)

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.